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Abstract
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant genetic disease 
caused by RET gene germline mutations that is characterized by medullary thyroid 
carcinoma (MTC) associated with other endocrine tumors. Several reports have 
demonstrated that the RET mutation profile may vary according to the geographical area. 
In this study, we collected clinical and molecular data from 554 patients with surgically 
confirmed MTC from 176 families with MEN2 in 18 different Brazilian centers to compare 
the type and prevalence of RET mutations with those from other countries. The most 
frequent mutations, classified by the number of families affected, occur in codon 634, 
exon 11 (76 families), followed by codon 918, exon 16 (34 families: 26 with M918T and 8 
with M918V) and codon 804, exon 14 (22 families: 15 with V804M and 7 with V804L). When 
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and some differences. While the mutations in codons C618, C620, C630, E768 and S891 
present a similar prevalence, some mutations have a lower prevalence in Brazil, and others 
are found mainly in Brazil (G533C and M918V). These results reflect the singular proportion 
of European, Amerindian and African ancestries in the Brazilian mosaic genome.
Introduction
Multiple endocrine neoplasia type 2 (MEN2) is an 
autosomal dominant genetic syndrome characterized by 
the association of endocrine tumors. MEN2 is classified 
into two subtypes, MEN type 2A (MEN2A; OMIM 
#171400) and MEN type 2B (MEN2B; OMIM #162300), 
according to its clinical manifestations, characterized by a 
high penetrance of medullary thyroid carcinoma (MTC), 
and to a lesser degree, pheochromocytoma (PHEO) and 
primary hyperparathyroidism (PHPT) (1, 2, 3, 4).
Despite being traditionally considered a rare disease, 
the earlier diagnosis and the discovery of asymptomatic 
carriers of MEN2 have increased its prevalence, from 
approximately 1 case per 200,000 or 500,000 inhabitants 
to possibly 1:80,000 inhabitants (5). As an example, in 
Norway, a country where epidemiological data from 
the entire population have recently been published, the 
incidence of patients with RET mutations associated with 
MEN2 was 1:66,438 live births, while the prevalence of 
MEN2 was 1:79,462 (6).
MEN2A and MEN2B are caused by germline mutations 
of the RET gene (7, 8, 9, 10, 11). The demonstration that 
RET mutations are associated with the MEN2 phenotype 
have altered not only the diagnosis but also the treatment 
of these patients, as they have enabled the identification 
of asymptomatic carriers who could be treated 
prophylactically. Moreover, a correlation between disease 
phenotype and the codon of the affected RET mutation 
was acknowledged (1, 2, 12). Since MTC occurs in 95% of 
MEN2A patients and RET mutations in different codons 
result in variable disease manifestations, investigations 
have been carried out to identify predictors for the optimal 
timing and extent of prophylactic thyroid surgery (13, 
14). Guidelines and treatment recommendations issued 
by the American Thyroid Association (ATA) and other 
associations were based on these studies (2, 3, 12, 15, 16).
A number of reports that included a large number of 
affected patients have demonstrated that the RET mutation 
profile may vary according to geographical area (5, 6, 17, 
18, 19, 20, 21, 22, 23). Brazil has a territory of continental 
size, with an area of 8.5 million square kilometers and a 
population of more than 209 million inhabitants, with 
a singular proportion of European, Amerindian and 
African ancestries in its mosaic genome (24, 25). Indeed, 
recent ethnographic fieldwork and haplotype analysis 
traced founder mutations from Brazil back to the Iberian 
Peninsula and Greece (20, 22). Of note, an international 
consortium (26) found that the penetrance of PHEO in 
MEN2 patients carrying RET mutations on exons 10 and 
11 is lower in countries from South America (including 
many patients from Brazil) than in Europe and proposed 
that other genetic or environmental modifiers could 
explain this difference. By the same token, we have shown 
a lower penetrance of PHEO in patients carrying the RET 
G533C mutation (exon 8) in Brazil than in Greece (27).
Considering the findings above, this study aimed to 
collect RET gene genotyping data from as many Brazilian 
families with MEN2 as possible, to analyze the distribution 
and frequency of RET mutations, and to compare the type 
and prevalence of RET mutations with those of other 
countries.
Patients and methods
The subjects of this study were 2201 individuals from 
176 kindreds who underwent RET molecular screening 
in 18 reference centers in Brazil. Since RET screening 
was established, each time a new patient with MTC was 
diagnosed, he or she underwent RET genotyping and a 
common protocol was followed by all centers following 
available guidelines (2, 3, 12, 15, 16). The following centers 
participated in this study: Universidade Federal de São 
Paulo (UNIFESP), Faculdade de Medicina, Universidade de 
São Paulo (FMUSP), and Instituto do Câncer do Estado de 
São Paulo (ICESP) in São Paulo; Universidade Federal do 
Rio Grande do Sul (UFRGS) in Porto Alegre; Universidade 
de Fortaleza (UNIFOR), Universidade Federal do Ceará 
(UFC), and Hospital Geral de Fortaleza (HGF) in Fortaleza; 
Instituto Nacional do Câncer (INCA) and Instituto 
Estadual de Diabetes e Endocrinologia (IEDE) in Rio de 
Janeiro; Universidade Federal do Espirito Santo (UFES) and 
Hospital Santa Rita de Cássia (HSR) in Vitória; Hospital 
de Câncer de Barretos (HCB) and Faculdade de Ciências 
da Saúde de Barretos Dr. Paulo Prata (FACISB) in Barretos; 
Endocrine Connections
(2019) 8, 289–298




https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/18/2020 01:27:54PM
via Unicamp, Univ Estadual de Campinas, Universidade Estadual de Campinas and Universidade Estadual Campinas
R M B Maciel, C P Camacho 
et al.
MEN2 in Brazil 2918:3
Universidade Estadual Paulista (UNESP) in Botucatu; 
Universidade de Campinas (UNICAMP) in Campinas; 
Faculdade de Medicina de Ribeirão Preto, Universidade 
de São Paulo (FMRP-USP) in Ribeirão Preto; Universidade 
Federal de Minas Gerais (UFMG) in Belo Horizonte and 
Universidade Federal do Paraná (UFPR) in Curitiba.
For the phenotypic classification, each center 
replied questionnaires that recorded individual clinical 
evaluations of patients and families according to the 
criteria proposed by the American Thyroid Association 
(ATA) (2) and the Brazilian Society of Endocrinology and 
Metabolism (16); additionally, all patients were staged 
according to the TNM (tumor, lymph nodes, metastases) 
classification system of the American Joint Committee on 
Cancer (AJCC)/TNM (28). After receiving the completed 
questionnaires, we organized the information from the 
worksheets and compiled the data in a unique document.
Informed consent from patients and approval by 
research ethics committees from all centers were obtained. 
All subjects received pre- and post-test genetic counseling. 
The study was approved by the Institutional Review Board 
and Ethics Committee of the Universidade Federal de São 
Paulo (CEP 1749/06).
When RET screening became a routine test in the 
Laboratory of Molecular and Translational Endocrinology 
of the Universidade Federal de São Paulo, in the beginning 
of 2002, all index cases and, when appropriate, their first-
degree relatives were screened for pathogenic mutations 
and also a prospective evaluation began. We performed 
sequencing of the hotspot exons and, when necessary, 
of the entire coding region of RET using DNA extracted 
from whole blood samples from patients from UNIFESP, 
UNIFOR, UFC, HGF, INCA, IEDE, UFES, UNICAMP, IEDE, 
UFMG and UFPR (29). Patients from UFRGS, FMUSP, 
ICESP, HCB, UNESP and FMRP-USP were genotyped 
following similar protocols in their respective laboratories 
using previously published techniques (30, 31, 32). When 
a mutation was identified in the index case, members 
of the family were screened accordingly using the 
criteria for gene autosomal dominant transmission and 
only at the involved exon. The data collected for each 
individual included the clinical characteristics of family 
members (association with other endocrine neoplasias), 
the RET mutation, presence of PHEO or primary 
hyperparathyroidism (PHPT) and information on other 
features noted, such as HSCR or CLA.
For the statistical analysis of the data, we first 
calculated the averages, medians, means, maximum and 
minimum values; we used the percentages considering the 
total number of cases for a specific phenotype or genotype. 
We analyzed the categorical variables by means of the chi-
square test with Fisher’s correction when appropriate; for 
continuous variables, we used the Kruskal–Wallis test. We 
used ‘IBM SPSS Statistics for Windows, version 25’ (IBM 
Corp.). We considered P < 0.05 as statistically significant.
Results
Table  1 shows the clinical and molecular results from 
MEN2 patients from 18 different Brazilian centers; overall, 
554 patients with surgically confirmed MTC from 176 
families were identified, indicating 30 different germline 
mutations in 12 codons of 7 exons (8, 10, 11, 13, 14, 15, 
16) of the RET gene.
In our series, we were able to determine the germline 
mutation for all patients with MEN2, which is different 
from other reports that present a small proportion of 
patients with negative RET genotyping. The most frequent 
mutations, classified by the number of families affected, 
occurred in codon 634, exon 11 (76 families), followed 
by codon 918, exon 16 (34 families: 26 with M918T and 
8 with M918V) and codon 804, exon 14 (20 families: 15 
with V804M and 7 with V804L).
When mutations were analyzed by the absolute 
number of patients with an established diagnosis of MTC 
after surgery, the most frequently found mutations were in 
codons 634 (262 patients, 47.3%), 533 (59 patients, 10.6%), 
620 (56 patients, 10.1%) and 918 (53 patients, 9.6%). 
Regarding the 262 patients affected by a mutation 
at codon 634, 166 were C634Y (63.4%), 74 were C634R 
(28.2%), 10 were C634W (3.8%), 8 were C634G (3.1%), 
3 were C634S (1.1%) and 1 was a C634F mutation 
(0.4%). In 47 of these cases, we observed that the Y791F 
variant co-occurred with the strong C634 mutation 
(C634/Y791F), as previously reported (33, 34, 35).
After MTC, the most frequently found association 
among patients with MEN2 was PHEO (21.3% of all 
patients). The codon-specific penetrance of PHEO showed 
that the penetrance was highest for patients with a C634 
mutation (79.2% of all patients with PHEO and 36.3% of 
all individuals with a mutation in codon 634), followed 
by codon M918T (10% of all patients with PHEO and 
37.5% of all with a mutation in codon M918T) and by 
codon C620 (5.8% of all patients with PHEO and 12.5% 
of all with a mutation in codon 620). PHPT and CLA were 
mainly described in patients with a mutation at codon 
634, with 46 and 42 cases, respectively. On the other 
hand, cases of HRSC were noted only in mutation carriers 
at codon 620.
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There was a predominance of women in our cohort 
(61.5%). For age, the youngest patient diagnosed with 
MTC was 5 years old and had a C634 mutation. For the 
M918T mutation, which is associated with the most 
aggressive form of MEN2, the youngest age at diagnosis 
was 6 years. Interestingly, we observed children carrying 
mutations in codons 611, 618, 620 (exon 10) and 
630 (exon 11), which are considered of moderate risk in 
the new ATA classification system, who were affected by 
MTC as early as 8 and 10 years old. On the other hand, the 
patients affected later carried mutations in codons V804L 
and V804M.
Table 2 shows the pathological characteristics of each 
mutation observed in our cohort. Higher proportions of 
non-T1 tumors were seen in the C618 (80%), V804L (71.4% 
of 7 cases) and M918T (65.4%) cases. In addition, lymph 
node metastases (N1) at diagnosis were more frequently 
seen in patients with M918T (78.6%), C620 (66.7%) and 
M918V (60%) mutations. Unfortunately, several patients 
presented with distant metastases at the time of diagnosis, 
including 39.3% of those with a mutation at the M918T 
codon, 23.8% of those with mutations at codon C620 and 
12.2% of those with mutations at the C634 codon.
Table  3 compares our results (n = 176 families, 554 
patients) with some of the largest published series in 
the literature, from Italy (n = 245 families), Germany 
(n = 191 families) and France (n = 444 families) (5, 18, 36), 
excluding patients with RET variant Y791F, currently 
considered a non-pathogenic variant (34). Although there 
were several similarities, we found several differences. 
While mutations in codons C618, C620, C630, E768 
and S891 presented a similar prevalence, mutations in 
codon L790 were more frequent in Germany and France 
(P < 0.01), as was the V804 mutation in Italy and France 
(P < 0.05). As for the C634 mutation, the prevalence in 
Brazil (43.2%) was higher than that in Italy and France 
(P < 0.05). The highest risk mutation, M918T, was more 
frequent in our study than in Italy (P < 0.05) and France 
(P < 0.01). The G533C and M918V mutations were found 
mainly in Brazil.
Discussion
Molecular epidemiology evaluates the contribution of 
genetic risk factors in the etiology, geographic distribution 
and prevention of a particular disease. Few areas of 
medicine have been so clearly affected by genetic diagnosis 
and management as MEN2, in which an activating 
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MTC in greater than 95% of mutation carriers. Since MTC 
is an aggressive disease that can eventually lead to death, 
early identification of asymptomatic carriers is essential, 
as it enables them to undergo prophylactic treatment by 
total thyroidectomy, increasing the chances of the disease 
being cured.
One interesting finding from the analysis of our 
data is that most of the literature presents the results of 
RET genotyping in relation to the number of families. 
However, as we have recently shown in studies of ancestry 
(20, 22), it is possible that many seemingly unrelated 
families actually present a common ancestor and thus 
would be considered one affected family, not several.
A correlation between genotypes and phenotypes was 
observed based on the analysis of the various mutations 
in the RET gene and their respective phenotypes. Age 
of onset and earliest age of lymph node metastases 
were factors taken into consideration to establish 
recommendations regarding the ideal time frame for 
prophylactic thyroidectomy. In addition, the prevalence 
of PHEO, primary hyperparathyroidism and their 
clinical presentation also served as a basis for current 
recommendations. In 2001, at the 7th International 
Workshop on MEN2 and MEN1, a guideline based on 
the indication for prophylactic thyroidectomy by the 
RET genotype (12) was proposed, which was followed 
by refinements resulting from new findings that 
demonstrated that prophylactic treatment was in fact 
justified, since it was associated with cure of the disease. 
These recommendations evolved into the guidelines of 
the ATA and other endocrine societies (2, 3, 15, 16).
However, with the increasing number of reports in 
terms of number of patients and geographies studied, 
some heterogeneity between the phenotypes of different 
families with the same RET mutation has been observed 
(2, 23, 37). This heterogeneity justifies the need for a 
global effort to describe families with MEN2 to clarify 
the genetic or environmental circumstances that would 
modify these phenotypes.
This study presents some of the largest data 
ever collected, with genetic screening leading to the 
characterization of 554 patients with hereditary MTC. 
Unlike other studies, we were able to determine the 
etiology of the RET mutation in all patients with MEN2. 
One explanation may be the execution of an extensive 
technique for genotyping that was not restricted to the 
exons where the most common mutations occur (hot 
spots) (29, 38). Another interesting finding is that the 
systematic execution of RET genotyping in all patients 
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in several families of patients that initially presented with 
apparently sporadic disease.
We were concerned about the older age of diagnosis in 
this Brazilian cohort, a factor that contributes to a greater 
morbidity of the disease. This can be partly explained by a 
lower awareness of the typical physical findings observed 
in MEN2B carriers among general pediatricians and 
endocrinologists (4, 39). Another concerning observation 
was the size of the lesions with a high frequency of non-T1 
tumors and the number of patients with distant metastases 
at initial presentation, suggesting poor access to health 
services and/or lower educational level, which affect early 
recognition of a health problem. On the other hand, we 
observed children carrying mutations in codons 611, 618, 
620 (exon 10) and 630 (exon 11), which are considered 
of moderate risk in the ATA classification system, who 
were affected by MTC as early as 8 and 10 years old; this 
observation is in line with recent data demonstrating that 
early onset of disease should be considered as a predictor 
for tumor aggressiveness (40).
The comparison of the BrasMEN results with some 
of the largest published series in the literature (5, 18, 36) 
– from Italy, Germany and France – showed similarities 
as well as differences (Table  3). While many mutations 
presented a similar prevalence, G533C and M918V were 
found mainly in Brazil. The M918T mutation, associated 
with MEN2B, was clearly more frequent in Brazil and 
Germany. Additionally, the most frequent mutation in 
codon C634 was C634Y.
The analysis of our data demonstrates a few 
peculiarities regarding RET mutations in Brazil. The first of 
these, based on the number of affected individuals, is the 
G533C mutation (41, 42). This family was originally from 
Barcelona, Spain and had migrated to the southeastern 
region of Brazil at the end of the nineteenth century. In our 
first description of the family, we mentioned that it would 
be plausible that individuals living in other countries could 
carry this mutation (41), since the Mediterranean Sea has 
always been a site of numerous migratory currents (42). 
Interestingly, as mentioned previously, some years later, 
Greek researchers described G533C as the most prevalent 
RET mutation in Greece (43, 44, 45, 46, 47); this mutation 
was also described in a family with Greek ancestors living 
in the United States (48) and in a patient living in Ireland 
Table 3 Comparison between mutation frequencies observed in BrasMEN and in 3 major published studies, Italy (18), Germany 
(5), and France (36).
RET codon
BrasMEN Italy Germany France
Families (n) % MTC cases (n) Families (n) % Families (n) % Families (n) %
T338 0 0 0 1 0.4 0 0 0 0
C515 0 0 0 1 0.4 0 0 2 0.5
dup531 0 0 0 0 0 0 0 1 0.2
G533 1 0.6 59 0 0 0 0 3 0.7
K603 0 0 0 0 0 0 0 1 0.2
C609 7 4.0 12 6 2.4 1 0.5 5 1.1
C611 6 3.4 12 1 0.4 6 3.1 12 2.7
C618 6 3.4 11 15 6.1 11 5.8 29 6.5
C620 6 3.4 56 9 3.7 14 7.3 31 7.0
C630 1 0.6 2 4 1.6 1 0.5 1 0.2
N631 0 0 0 0 0 0 0 0 0
C634 76 43.2 262 86 35.1 73 38.2 144 32.4
S649 0 0 0 0 0 0 0 2 0.5
K666 0 0 0 1 0.4 0 0 7 1.6
E768 6 3.4 14 9 3.7 2 1.0 14 3.2
L790 3 1.7 4 8 3.3 26 13.6 43 9.7
V804 23 12.5 46 52 21.2 19 9.9 95 21.4
M848 0 0 0 1 0.4 0 0 0 0
A883 0 0 0 1 0.4 0 0 3 0.7
S891 8 4.5 23 23 9.4 6 3.1 20 4.5
S904 0 0 0 1 0.4 0 0 0 0
R912 0 0 0 0 0 0 0 1 0.2
M918T 26 14.8 32 20 8.2 32 16.8 29 6.5
M918V 8 4.5 21 0 0 0 0 1 0.2
No mutations 0 0 0 6 2.4 0 0 0 0
Total 176 100 554 245 100 191 100 444 100
All variants of unknown significance (VUS) have been excluded, including Y791F, now considered as non-pathogenic (34).
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who was from Slovenia, another Mediterranean country 
(49). In view of these findings, we speculate that these 
families could have a common ancestor, as there have 
been several Greek city-states scattered throughout the 
Mediterranean since ancient times, including the Iberian 
Peninsula, where Barcelona is located (42). We confirmed 
this hypothesis by demonstrating that Brazilian patients 
(via Barcelona) and Greek patients have a common 
ancestor (22), a fascinating finding that suggests that, 
historically, the most plausible explanation for the origin 
of this mutation is that it occurred first in Greece and that 
the Greek migratory currents have taken it to the Iberian 
Peninsula; the fact that G533C is the most prevalent 
mutation in Greece reinforces this hypothesis.
Another important finding of our series was the 
discovery of the M918V mutation in the state of Ceará 
(20). Codon 918 is classically related to MEN2B and 
has been extensively studied since 1994, when the first 
mutation represented by a methionine substitution by 
threonine (M918T) was described (9, 10, 11). Subsequently, 
researchers demonstrated that, of all possible substitutions 
at codon 918, only the M918T mutation showed a high 
transforming activity (50). In our study, in view of the 
clinical presentation of MTC related to M918V and the 
results of previous in silico and in vitro analyses (51), it 
was suggested that this exchange should be considered a 
moderate-risk mutation (2, 20).
In our opinion, however, the most interesting finding 
of our research concerning the M918V mutation was the 
complete study of its founding effect and the age of the 
founder mutation. At first, we thought that they were 
isolated families, but the haplotype study showed that 
all these patients had a common ancestor, and through 
historical and mathematical studies we have confirmed 
the existence of a pioneer who emigrated from Braga, 
Portugal, to Brazil in 1700, corroborating our hypothesis 
that this mutation accompanied the population of this 
region for approximately 350–400  years and that these 
supposedly different families belong to a single family 
that has been fragmented over the centuries.
Investigations from our group also contributed to 
determining that RET Y791F-only does not indicate an 
increased MTC risk (34). In addition, we have shown 
that patients with MEN2 who were initially reported to 
be RET Y791F-only carriers were also found to harbor 
other associated disease-causing RET variants (C634Y 
in cis), leading to the disease. Importantly, this 
arrangement modifies completely the clinical situation, 
and patients with Y791F/C634Y should be treated 
accordingly to the recommendations to those carrying 
RET 634 mutations, in which total thyroidectomy must 
be performed (33, 34, 35).
The findings that the mutations in the RET gene in 
Brazil bear a certain resemblance to those of the European 
population but also have some differences, which is 
explained by data on the genomic ancestry of Brazilians, 
indicate a high ancestral variability and that each 
Brazilian has a singular and quite individual proportion 
of European, African and Amerindian ancestry in his/her 
mosaic genome (24, 25). In all Brazilian regions studied, 
European ancestry was predominant, with proportions 
ranging from 60.6% in the northeast to 77.7% in the 
south. According to Pena et  al., the immigration of six 
million Europeans to Brazil in the 19th and 20th centuries 
is largely responsible for dissipating previous ancestry 
dissimilarities that reflect region-specific population 
stories (25).
Despite the high number of patients included in this 
study, it has some limitations, as we do not yet have a 
nationwide view of the characteristics of MEN2 mutations 
in Brazil, since the centers that contributed the most in 
this study are located in the south and southeast regions; 
we had a good volume of patients from the northeast 
region, but since they were all from only two states, our 
observations have some bias. It should be emphasized 
that we studied only patients with the diagnosis of MTC 
and we did not include asymptomatic carriers.
In conclusion, this study enabled a more 
comprehensive understanding of RET mutations and the 
MEN2 phenotype distribution and prevalence in Brazil. 
This is one of the largest cohorts of MEN2 patients, and 
it is the first and a unique study collecting data from the 
majority of Brazilian centers involved in the diagnosis 
and treatment of thyroid cancer.
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